CRSP

#1262
CRISPR Therapeutics AG
56.71 USD
+3.43%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
56.33
56.97
Rango anual
33.03
78.48
Cambio diario
+3.43%
Variación mensual
+14.57%
Variación en los últimos 6 meses
-19.04%
Cambio anual
+47.95%
Cierres anteriores
54.83
Abrir
56.63
Bid
Ask
Mínimo
56.33
High
56.97
Volumen
370
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 5.44 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-8.11
Relación precio/flujo de caja
1 343.5

CRISPR Therapeutics AG

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Noticias